19.06.2017 21:38:16
|
Seattle Genetics Climbs Well Off Worst Levels But Remains Firmly Negative
(RTTNews) - Shares of Seattle Genetics (SGEN) have climbed well off their worst levels but continue to see notable weakness in late-day trading on Monday. After hitting a four-month intraday low, Seattle Genetics is currently down by 3.7 percent.
The initial drop by Seattle Genetics came after the biotechnology company said it is halting a late-stage trial of trial of vadastuximab talirine in frontline older acute myeloid leukemia patients.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Seattle Genetics Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |